資料載入中.....
|
請使用永久網址來引用或連結此文件:
https://ir.cnu.edu.tw/handle/310902800/34707
|
| 標題: | Real-world effectiveness of direct-acting antivirals in people living with human immunodeficiency virus and hepatitis C virus genotype 6 infections |
| 作者: | Sun, Hsin-Yun
Cheng, Chien-Yu
Lin, Chi-Ying
Yang, Chia-Jui
Lee, Nan-Yao
Liou, Bo-Huang
Tang, Hung-Jen
Liu, Yuang-Meng
Lee, Chun-Yuan
Chen, Tun-Chieh
Huang, Yi-Chia
Lee, Yuan-Ti
Tsai, Ming-Jui
Lu, Po-Liang
Tsai, Hung-Chin
Wang, Ning-Chi
Hung, Tung-Che
Cheng, Shu-Hsing
Hung, Chien-Ching |
| 貢獻者: | National Taiwan University
National Taiwan University Hospital
National Taiwan University
National Yang Ming Chiao Tung University
National Taiwan University
National Taiwan University Hospital
Far Eastern Memorial Hospital
National Yang Ming Chiao Tung University
National Cheng Kung University
National Cheng Kung University Hospital
Mackay Memorial Hospital
Chi Mei Hospital
Chia Nan University of Pharmacy & Science
Changhua Christian Hospital
Kaohsiung Medical University
Kaohsiung Medical University Hospital
Kaohsiung Medical University
Kaohsiung Medical University
National Taiwan University
National Taiwan University Hospital
Chung Shan Medical University
Chung Shan Medical University Hospital
Chung Shan Medical University
Kaohsiung Medical University
Kaohsiung Medical University Hospital
Kaohsiung Medical University
Kaohsiung Veterans General Hospital
National Defense Medical Center
Tri-Service General Hospital
National Taiwan University
China Medical University Taiwan
China Medical University Hospital - Taiwan
China Medical University Taiwan |
| 關鍵字: | taiwan consensus statement
therapy
management |
| 日期: | 2022 |
| 上傳時間: | 2023-12-11 14:06:18 (UTC+8) |
| 出版者: | BAISHIDENG PUBLISHING GROUP INC |
| 摘要: | BACKGROUND Hepatitis C virus (HCV) genotype 6 (HCV-6) infection is prevalent predominantly in Southeast Asia, and the data on the virologic response of HCV-6 to direct-acting antivirals (DAAs) are sparse in people living with human immunodeficiency virus (HIV) (PLWH). AIM To assess the virologic response of HCV-6 to DAAs in PLWH. METHODS From September 2016 to July 2019, PLWH coinfected with HCV-6 initiating DAAs were included. Laboratory investigations were performed at baseline, the end of treatment, and 12 wk off-therapy. RESULTS Of the 349 PLWH included (mean age 48.9 years, 82.5% men), 80.5% comprised people who inject drugs, 18.1% men who have sex with men, and 1.4% heterosexuals. Coexistent hepatitis B virus infection was present in 12.3% of the included PLWH, liver cirrhosis 10.9%, hepatocellular carcinoma 0.9%, and previous HCV treatment experience 10.9%. The mean baseline plasma HCV RNA was 6.2 log 10 IU/mL. Treatment with glecaprevir/pibrentasvir was initiated in 51.9%, sofosbuvir/ledipasvir 41.5%, sofosbuvir/velpatasvir 6.3%, and sofosbuvir/daclatasvir 0.3%. At DAA initiation, antiretroviral therapy containing tenofovir alafenamide was given in 26.4%, tenofovir disoproxil fumarate 34.4%, non-tenofovir alafenamide/tenofovir disoproxil fumarate 39.3%, non- nucleoside reverse-transcriptase inhibitors 30.4%, protease inhibitors 4.0%, and integrase strand transfer inhibitors 66.8%; 94.8% of the included patients had CD4 counts = 200 cells/mm3 and 96.0% had plasma HIV RNA < 50 copies/mL. Overall, 96.8% achieved undetectable plasma HCV RNA (< 30 IU/mL) at end of treatment; and 92.3% achieved sustained virologic response 12 wk off-therapy in the intention-to-treat analysis (93.5% in patients receiving sofosbuvir-based DAAs and 91.2% in those receiving glecaprevir/pibrentasvir). CONCLUSION Similar to the observation made in HIV-negative patients, sustained virologic response 12 wk offtherapy with DAAs is high in PLWH coinfected with HCV-6. |
| 關聯: | WORLD JOURNAL OF GASTROENTEROLOGY, v.28, n.CB2, pp.CC2, pp.-, |
| 顯示於類別: | [行政單位] 123
|
文件中的檔案:
| 檔案 |
描述 |
大小 | 格式 | 瀏覽次數 |
|---|
| index.html | | 0Kb | HTML | 84 | 檢視/開啟 |
|
在CNU IR中所有的資料項目都受到原著作權保護.
|
